mographic, cultural, and institutional structures.
International comparisons of health expenditures are complicated because countries often define the boundaries of their health sectors differently. This occurs because of differences in the treatment of items such as school and prison health services, occupational health, and environmental health, as well as the subjective nature and inherent difficulty of distinguishing between medical versus social services. Thus, health sector boundaries differ because of both differences in subjective evaluations and actual classification practices.
As a result, comparability of data is a significant, albeit frequently neglected, problem in international comparisons. The data employed in this analysis were collected by the OECD over a three-year period in an effort to establish comparable time series data and were recently published in Measuring Health Care 1960 Care -1983 . 2 This information is based on national accounts data supplemented by other comparable sources. While the data are not exactly analogous, they represent the most systematic effort to date in terms of data consistency and longitudinal nature. Based on Standardized National Accounts definitions of spending aggregates, public health expenditures are defined to be tranfers to households (directly or to medical care providers on their behalf), collective health services financed by government (including administrative costs, research, and development), and public investment in hospitals, clinics, and the like, and related capital transfers. Total (national) health expenditures include public expenditures as well as private consumption of households, whether financed out-of-pocket, by private insurance, or by charities. Medical care prices are the implicit price deflators for the purchase of medical goods and services by private households.
The most difficult problem in international comparisons of health expenditures is lack of appropriate measures of health outcomes. Without such measures, one cannot readily evaluate the overall or marginal impacts of health expenditures on health outcomes. Given both the conceptual and measurement problems in developing such indices, most international studies compare inputs or intermediate outputs (for example, hospital days). ronmental factors, industrial and occupational mixes, public and private health insurance coverage, cost-sharing, reimbursement systems, absolute and relative price structures, provision of health-related social services, medical practice patterns and the availability of certain medical technologies, efficiency and productivity, administrative costs, and legal systems. While the effects of some of these factors, such as age structure, can be accounted for empirically, others cannot.
International comparisons of health expenditures (indeed all financial aggregates) are rendered difficult because both overall price levels and relative prices for specific commodities generally differ across countries. The usual procedure in comparing absolute differences in per capita spending across countries is simply to calculate per capita spending in each country, then convert those figures into a common numeraire by using market exchange rates. However, since market exchange rates do not fully reflect either relative or absolute price differences, the resulting per capita spending figures, when measured. in terms of a common currency, reflect not only volume differences, but price differences as well. In other words, although the exchange rate converted expenditures are expressed in the same currency unit, they are not expressed in the same set of prices. Both the European Community and OECD are currently working on the development of price indices, called purchasing power parities (PPPs), which correct for these price differences in exchange rate based comparisons.
PPPs are essentially international price indices which compare the prices of the same set of commodities among different countries. They are, in effect, exchange rates which express the rate at which one currency should be converted into another in order to purchase the equivalent set of goods in both countries. 4 PPPs have been developed for GDP and its components, For health, they are the ratio of national average health prices in one country to the corresponding average international prices for the entire comparative group of countries. Dividing expenditures by PPPs results in a measure of volume which reflects valuing each country's health services relative to the average international prices of those services. However, since the health PPPs are in a rather early stage of development and given the greater reliability of the GDP PPPs, the latter are employed in the analysis below. differences, there still appears to be a greater than threefold difference in the "volume" of services consumed across the OECD countries. To see if per capita health expenditures are related to a country's wealth as measured by its per capita GDP, we examined the relationship between per capita health expenditures and per capita GDP for the twenty-one countries for 1984. (See Exhibit 2). The data points and the "best fitting" trend line indicate a statistically significant relationship in which each $100 difference in per capita GDP is associated with a $10.50 difference in per capita health expenditures. The calculated elasticity is 1.4 indicating that each 10 percent difference in per capita GDP is associated with a 14 percent difference in per capita health expenditures. Futhermore, the analysis indicates that variations in per capita GDP, alone, are associated with 77 percent of the variation in per capita health spending. Other analyses have shown a direct and statistically significant relationship between the share of health in GDP and per capita GDP. health services.
Exhibit 3 contains data on the ratio of total health expenditures to GDP as well as the ratio of public to total health spending. In 1984, health spending in the eighteen OECD countries (for which data were consistently available for all six different years) was on average 7.5 percent of GDP. The United States, 10.7 percent, had the highest GDP share, while Greece, 4.6 percent, had the lowest. The distribution of GDP shares around the mean is far more condensed than the distribution of per capita spending as indicated by a coefficient of variation of .2, compared to that of .39 for per capita spending.
The share of health in GDP has grown significantly on average and for all countries, Health expenditures increased from 4. Individual country experiences varied widely over this time period with all countries experiencing growth. By 1984, France, Ireland, Japan, the Netherlands, Spain, Sweden, Switzerland, and the United States had experienced at least a doubling of their health to GDP ratios. On the other hand, Australia, Canada, Greece, Iceland, and the United Kingdom experienced increases of less than 60 percent. The most rapid growth generally took place in those countries with relatively low health to GDP ratios in 1960.
Public expenditures as a percent of total health spending also increased from an OECD average of 61 percent in 1960 to 78.7 percent in 1984. Most of the growth in the public share had occured by 1975 when the public share reached 76 percent. Since then the public share has increased by only 3 percentage points. This is consistent with expansion of public programs in the 1960s and saturation in the late 1970s. One critical policy question is if this leveling off in the public share will be followed by a major reversal as individual countries seek to cope with their health care financing problems by restricting public expenditures and relying on private financing.
Public shares in 1984 varied widely among countries from a low of 41 percent in the United States (49 percent if tax expenditures are included) to 80 percent or more in Australia, Belgium, Denmark, Iceland, Ireland, Italy, Norway, Sweden, and the United Kingdom. Growth in public shares and maturation of public programs differed widely, since the public systems accounted for 80 percent or more of all spending in only three countries in 1960 compared to at least nine in 1984.
Also worthy of note is the significance of the private sector. In at least seven countries, the private sector accounts for over 25 percent of health expenditures. Thus, while analyses based only on public spending may provide useful information about government budgets, they will not provide a complete picture of overall health expenditures in a significant number of countries. Clearly, private sector financing and ownership are important aspects of most OECD health systems.
Real Growth In Health Expenditures Relative To GDP
To analyze growth in real health expenditures relative to growth in real GDP, the real elasticities of health expenditures relative to GDP are calculated for each of eighteen countries. They indicate the percentage changes in real health expenditures relative to the percentage changes in real GDP.
Exhibit 4 contains the real elasticities of total health spending relative to GDP. Real health spending and real GDP are calculated by dividing the nominal figures by the medical care price index and the GDP defla- The elasticity for the overall period can bc greater or less than the elasticities for the two subperiods if a major structural shift in the relationship has occurred between the two periods. In this case the slope of the logarithmic regression line, the elasticity. can be greater or less than the slopes for the two subperiods. 
Exhibit 4 Real Elasticities Of Total Health Expenditures

Decomposition Of Health Expenditure Increases
Growth in nominal health expenditures can be disaggregated into increases in overall inflation in the economy, health care inflation in excess of overall inflation, increases in population, and increases in average real benefits per person. Average real benefits per capita is the residual after adjustment of nominal expenditures for price and population growth. This factor reflects all other factors not adequately controlled for by the price and population variables. For purposes of this analysis, this factor is called the utilization/ intensity effect. 6 Exhibit 5 contains the disaggregation of increases in overall health spending into price, population, and utilization/ intensity effects for the seven largest OECD countries for 1960-84. 7 Over the twenty-four-year period, average nominal spending for the seven countries increased at a compound annual rate of 13.9 percent. Health care prices increased at 7 .0 percent, population at 0.8 percent, and utilization/ intensity per person at 5.6 percent. These data clearly suggest that the principal growth factors are health care inflation and increases in utilization/ intensity of services per person with population growth being only a minor contributor. However, a somewhat different picture emerges when one compares health care price inflation with general economic inflation. Disaggregating health care price increases into general price increases and health care price increases in excess of overall inflation, general prices increased by 6.8 percent, while health care price increases in excess of general price increases were only 0.1 percent. In other words, between 1960 and 1984 health care price inflation exceeded overall inflation by only 0.1 of a percentage point. Thus, if one takes general economic inflation as given increases in utilization/ intensity of services per person is the single largest endogenous factor affecting health care expenditure increases. Indeed, policies undertaken by many OECD countries, such as the hospital prospective payment systems in the United States and France, limits on overall physician expenditures in certain Canadian provinces, and limitations imposed by France, Germany, and the United Kingdom on their lists of reimbursable pharmaceuticals are attempts to deal with the utilization/ intensity issue. 
DATAWATCH 121
The decomposition of health spending for individual countries mirrors the overall pattern with some exceptions. Over the 1960-84 period, nominal spending increased at compound annual rates from a low of 10.1 percent in Germany to a high of 17.6 in Italy. Nominal spending in the United States over this period increased by 11.8 percent. Adjusting for health price increases results in real spending increased from 4.2 percent in Germany to 10.2 in Japan. In the United States, real spending increased by 5.3 percent. After taking account of population growth, increases in real per capita utilization/ intensity ranged from a low of 3.8 in Germany to a high of 9.1 in Japan. Real per capita utilization/ intensity in the United States increased at a compound average annual rate of 4.1 percent, ranking the United States fifth out of seven countries in terms of growth in real benefits per capita. Thus, all seven countries experienced substantial increases in real per capita benefits over this period. The results here are not surprising. Indeed, detailed studies within individual countries such as that of Freeland and Schendler in the United States go well beyond the aggregate statistics presented here by disaggregating the utilization/ intensity effect into separate intensity and utilization effects. 8 What is of interest is both the commonality of experience among these seven countries in terms of utilization/ intensity being the single largest growth factor after general inflation in all seven countries, and also the rather nonanalogous experiences regarding the fact that four of the seven countries, in retrospect, did not appear to have had a measured excess health care price inflation problem. Whether this is due to strict regulation of health care prices in these countries or methodological nuances in the price indices cannot be easily discerned. In any event, in the United States health care inflation exceeded overall inflation by 1 percentage point.
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Conclusion
Despite cultural, institutional, demographic, and economic differences, health care expenditures in the OECD countries have displayed similar patterns of overall growth as well as growth relative to GDP. Increases in utilization/ intensity of services appear to have been the major endogenous factor driving health care expenditures. While the aggregate data analyzed here provide only a general picture of overall trends, they are based on more or less consistent definitions of health expenditure aggregates. Future comparative policy analyses will require disaggregation of expenditures as well as concomitant price and utilization information. Standardization of definitions and concepts will be of critical importance to the validity of the results.
However, of most importance is the development of valid measures of health outcomes. Without such measures, one cannot evaluate the ulti- mate effectiveness of health care spending. Despite similar trends in health expenditure increases in OECD countries, there are still sizable differences in levels of health spending as well as significant differences in age-adjusted death rates, life expectancy, and other available health status indices. Cross-national exchanges of information can provide important inputs to national policymakers as they grapple with the difficult problem of assessing the effectiveness of health service expenditures.
The views expressed in this paper are those of the authors and do not necessarily represent those of the Organization for Economic Cooperation and Development.
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